Pivotal phase III COMPOSE trial will compare (177)Lu-edotreotide with best standard of care for well-differentiated aggressive grade 2 and grade 3 gastroenteropancreatic neuroendocrine tumors Meeting Abstract
| Authors: | Halfdanarson, T. R.; Reidy, D. L.; Vijayvergia, N.; Halperin, D. M.; Goldstein, G.; Kong, G.; Michael, M.; Leyden, S.; Grozinsky-Glasberg, S.; Sorbye, H.; Oberg, K. E.; Sierras, C.; Harris, P. |
| Abstract Title: | Pivotal phase III COMPOSE trial will compare (177)Lu-edotreotide with best standard of care for well-differentiated aggressive grade 2 and grade 3 gastroenteropancreatic neuroendocrine tumors |
| Meeting Title: | 2022 ASCO Gastrointestinal Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 4 Suppl. |
| Meeting Dates: | 2022 Jan 20-22 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-02-01 |
| Language: | English |
| ACCESSION: | WOS:000770995900499 |
| DOI: | 10.1200/JCO.2022.40.4_suppl.TPS514 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: TPS514 -- Meeting was conducted online as well as in person -- Source: Wos |
